• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Wednesday's Pre-Market Session

    8/23/23 9:06:11 AM ET
    $APLS
    $AXLA
    $CPHI
    $GMVD
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $APLS alert in real time by email

    Gainers

    • GRI Bio (NASDAQ:GRI) stock increased by 65.7% to $4.44 during Wednesday's pre-market session. The market value of their outstanding shares is at $13.1 million.
    • ITeos Therapeutics (NASDAQ:ITOS) shares increased by 41.19% to $16.59. The company's market cap stands at $593.6 million.
    • Arcus Biosciences (NYSE:RCUS) stock increased by 35.72% to $25.53. The company's market cap stands at $1.9 billion.
    • Apellis Pharmaceuticals (NASDAQ:APLS) shares increased by 26.46% to $38.9. The market value of their outstanding shares is at $4.5 billion.
    • Kiora Pharmaceuticals (NASDAQ:KPRX) shares moved upwards by 19.64% to $0.61. The company's market cap stands at $4.4 million.
    • Vaccinex (NASDAQ:VCNX) shares increased by 13.68% to $0.25. The company's market cap stands at $16.4 million.

    Losers

    • Mallinckrodt (AMEX:MNK) shares fell 21.8% to $0.46 during Wednesday's pre-market session. The company's market cap stands at $6.1 million.
    • China Pharma Holding (AMEX:CPHI) stock declined by 11.67% to $0.26. The company's market cap stands at $2.9 million.
    • G Medical Innovations (NASDAQ:GMVD) stock fell 10.67% to $0.16. The company's market cap stands at $1.5 million.
    • SeqLL (NASDAQ:SQL) shares decreased by 9.1% to $0.32. The company's market cap stands at $4.4 million.
    • Heart Test Laboratories (NASDAQ:HSCS) stock declined by 7.08% to $0.65. The company's market cap stands at $6.7 million.
    • Axcella Health (NASDAQ:AXLA) stock declined by 6.79% to $0.16. The market value of their outstanding shares is at $11.9 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $APLS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $APLS
    $AXLA
    $CPHI
    $GMVD

    CompanyDatePrice TargetRatingAnalyst
    Apellis Pharmaceuticals Inc.
    $APLS
    3/13/2026$31.00Buy
    Roth Capital
    Arcus Biosciences Inc.
    $RCUS
    2/12/2026$23.00Overweight → Equal Weight
    Wells Fargo
    Apellis Pharmaceuticals Inc.
    $APLS
    1/28/2026$24.00Equal Weight
    Barclays
    Apellis Pharmaceuticals Inc.
    $APLS
    1/21/2026$28.00Neutral → Buy
    BofA Securities
    Arcus Biosciences Inc.
    $RCUS
    1/13/2026$28.00Neutral → Buy
    Goldman
    Arcus Biosciences Inc.
    $RCUS
    1/8/2026$20.00Overweight → Equal-Weight
    Morgan Stanley
    Apellis Pharmaceuticals Inc.
    $APLS
    11/6/2025Peer Perform
    Wolfe Research
    Apellis Pharmaceuticals Inc.
    $APLS
    10/15/2025$32.00Overweight
    Wells Fargo
    More analyst ratings

    $APLS
    $AXLA
    $CPHI
    $GMVD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Francois Cedric gifted 64,869 shares and received a gift of 64,869 shares, decreasing direct ownership by 13% to 425,968 units (SEC Form 4)

    4 - Apellis Pharmaceuticals, Inc. (0001492422) (Issuer)

    3/13/26 4:02:04 PM ET
    $APLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Kiora Pharmaceuticals Inc.

    4 - KIORA PHARMACEUTICALS INC (0001372514) (Issuer)

    3/10/26 4:36:21 PM ET
    $KPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Kiora Pharmaceuticals Inc.

    4 - KIORA PHARMACEUTICALS INC (0001372514) (Issuer)

    3/10/26 4:37:12 PM ET
    $KPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APLS
    $AXLA
    $CPHI
    $GMVD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Roth Capital initiated coverage on Apellis Pharmaceuticals with a new price target

    Roth Capital initiated coverage of Apellis Pharmaceuticals with a rating of Buy and set a new price target of $31.00

    3/13/26 8:46:55 AM ET
    $APLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Arcus Biosciences downgraded by Wells Fargo with a new price target

    Wells Fargo downgraded Arcus Biosciences from Overweight to Equal Weight and set a new price target of $23.00

    2/12/26 7:22:07 AM ET
    $RCUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Barclays initiated coverage on Apellis Pharmaceuticals with a new price target

    Barclays initiated coverage of Apellis Pharmaceuticals with a rating of Equal Weight and set a new price target of $24.00

    1/28/26 7:15:29 AM ET
    $APLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APLS
    $AXLA
    $CPHI
    $GMVD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    HeartSciences Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update

    Southlake, Texas, March 16, 2026 (GLOBE NEWSWIRE) -- HeartSciences Inc.  (NASDAQ:HSCS, HSCSW)) ("HeartSciences" or the "Company"), a healthcare information technology ("HIT") company focused on advancing electrocardiography ("ECG" or "EKG") through the integration of artificial intelligence ("AI"), today reported financial results for its fiscal third quarter ended January 31, 2026 ("FQ3 2026") and provided a business update. Third Quarter and Recent Highlights During the third quarter and subsequent period, the Company continued advancing the commercialization of its MyoVista Insights™ healthcare IT platform and submitted its MyoVista® wavECG™ device to the U.S. Food and Drug Administra

    3/16/26 4:15:00 PM ET
    $HSCS
    Industrial Specialties
    Health Care

    Arcus Biosciences Announces New Employment Inducement Grants

    Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune diseases, today announced that the Compensation Committee of the Company's Board of Directors granted two new employees options to purchase a total of 17,050 shares of the Company's common stock at an exercise price per share of $23.43, which was the closing price on March 9, 2026, and restricted stock units to acquire a total of 8,550 shares of the Company's common stock. The equity awards were granted pursuant to the Company's 2020 Inducement Plan, which was approved by the Co

    3/9/26 4:35:00 PM ET
    $RCUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Apellis Announces Mikael Dolsten, M.D., Ph.D., to Join Board of Directors

    WALTHAM, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) announced today that Mikael Dolsten, M.D., Ph.D., has joined the company's board of directors as of March 1. Most recently, Dr. Dolsten served for more than 16 years as chief scientific officer and president, worldwide research, development and medical, at Pfizer, during which he presided over the regulatory approval of more than 36 medicines and vaccines.  "We are thrilled to welcome Mikael to the Apellis Board of Directors," said Cedric Francois, M.D., Ph.D., chief executive officer and co-founder, Apellis. "Mikael is a proven industry leader with deep experience developing innovative medicine

    3/2/26 7:00:00 AM ET
    $APLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APLS
    $AXLA
    $CPHI
    $GMVD
    SEC Filings

    View All

    SEC Form DEF 14A filed by HeartSciences Inc.

    DEF 14A - HeartSciences Inc. (0001468492) (Filer)

    3/17/26 4:16:35 PM ET
    $HSCS
    Industrial Specialties
    Health Care

    HeartSciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - HeartSciences Inc. (0001468492) (Filer)

    3/16/26 4:15:52 PM ET
    $HSCS
    Industrial Specialties
    Health Care

    SEC Form 10-Q filed by HeartSciences Inc.

    10-Q - HeartSciences Inc. (0001468492) (Filer)

    3/16/26 4:04:49 PM ET
    $HSCS
    Industrial Specialties
    Health Care

    $APLS
    $AXLA
    $CPHI
    $GMVD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Ecor1 Capital, Llc bought $38,685,562 worth of shares (4,958,978 units at $7.80) (SEC Form 4)

    4 - iTeos Therapeutics, Inc. (0001808865) (Issuer)

    5/16/25 6:52:07 PM ET
    $ITOS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Kaneko Yasunori bought $201,200 worth of shares (20,000 units at $10.06), increasing direct ownership by 238% to 28,400 units (SEC Form 4)

    4 - Arcus Biosciences, Inc. (0001724521) (Issuer)

    2/27/25 7:06:05 PM ET
    $RCUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Rosen Terry J bought $201,465 worth of shares (19,800 units at $10.18), increasing direct ownership by 0.78% to 2,554,160 units (SEC Form 4)

    4 - Arcus Biosciences, Inc. (0001724521) (Issuer)

    2/27/25 7:05:56 PM ET
    $RCUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APLS
    $AXLA
    $CPHI
    $GMVD
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for EMPAVELI issued to APELLIS PHARMACEUTICALS INC

    Submission status for APELLIS PHARMACEUTICALS INC's drug EMPAVELI (ORIG-1) with active ingredient PEGCETACOPLAN has changed to 'Approval' on 05/14/2021. Application Category: NDA, Application Number: 215014, Application Classification: Type 1 - New Molecular Entity

    5/17/21 11:09:40 AM ET
    $APLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APLS
    $AXLA
    $CPHI
    $GMVD
    Leadership Updates

    Live Leadership Updates

    View All

    Apellis Announces Mikael Dolsten, M.D., Ph.D., to Join Board of Directors

    WALTHAM, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) announced today that Mikael Dolsten, M.D., Ph.D., has joined the company's board of directors as of March 1. Most recently, Dr. Dolsten served for more than 16 years as chief scientific officer and president, worldwide research, development and medical, at Pfizer, during which he presided over the regulatory approval of more than 36 medicines and vaccines.  "We are thrilled to welcome Mikael to the Apellis Board of Directors," said Cedric Francois, M.D., Ph.D., chief executive officer and co-founder, Apellis. "Mikael is a proven industry leader with deep experience developing innovative medicine

    3/2/26 7:00:00 AM ET
    $APLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    TTM Technologies, Dutch Bros, Advanced Energy Industries, and American Healthcare REIT Set to Join S&P MidCap 400; Others to Join S&P SmallCap 600

    NEW YORK, Jan. 27, 2026 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P MidCap 400, S&P SmallCap 600: S&P SmallCap 600 constituent TTM Technologies Inc. (NASD: TTMI) will replace Civitas Resources Inc. (NYSE:CIVI) in the S&P MidCap 400, and Amneal Pharmaceuticals Inc. (NASD: AMRX) will replace TTM Technologies in the S&P SmallCap 600 effective prior to the opening of trading on Friday, January 30. S&P SmallCap 600 constituent SM Energy Co. (NYSE:SM) is acquiring Civitas Resources in a deal expected to be completed soon, pending final closing conditions. SM Energy will remain in the S&P SmallCap 600 post-merger.Dutch Bros Inc. (NYSE:BROS) will replace Potlatc

    1/27/26 6:02:00 PM ET
    $AEIS
    $AHR
    $AMRX
    Industrial Machinery/Components
    Technology
    Real Estate Investment Trusts
    Real Estate

    HeartSciences Adds Prominent Key Advisors to its Scientific Advisory Board

    Southlake, TX, May 07, 2025 (GLOBE NEWSWIRE) -- HeartSciences Inc. (NASDAQ:HSCS) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announced the appointment of Dr. Girish Nadkarni, MD, Dr. Joshua Lampert, MD, and Dr. Akhil Vaid, MBBS, to its Scientific Advisory Board. These appointments underscore HeartSciences' commitment to advancing and transforming data-driven AI-ECG technology. "We are honored to welcome Dr. Girish Nadkarni, Dr. Joshua Lampert, and Dr. Akhil Vaid to our Scientific Advisory Board," said Andrew Simpson, CEO of HeartScien

    5/7/25 9:00:00 AM ET
    $HSCS
    Industrial Specialties
    Health Care

    $APLS
    $AXLA
    $CPHI
    $GMVD
    Financials

    Live finance-specific insights

    View All

    Arcus Biosciences Reports Fourth-Quarter and Full-Year 2025 Financial Results and Provides a Pipeline Update

    Updated data for casdatifan in late-line kidney cancer demonstrated median progression-free survival (PFS) of 15.1 months and a confirmed overall response rate (cORR) of 45% for the 100mg once-daily (QD) cohort At least two additional data presentations for casdatifan are expected in 2026: updated data for casdatifan plus cabozantinib and initial data in early-line kidney cancer In addition to the ongoing Phase 3 PEAK-1 study, Arcus plans to initiate a Phase 3 study in the first-line (1L) metastatic setting evaluating casdatifan in a tyrosine kinase inhibitor (TKI)-free combination by the end of 2026 With $1.0 billion in cash, cash equivalents and marketable securities at year-

    2/25/26 4:05:00 PM ET
    $RCUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results

    Full-year 2025 net product revenues of $689 million SYFOVRE® (pegcetacoplan injection) full year 2025 net product revenue of $587 millionEMPAVELI® (pegcetacoplan) full year 2025 net product revenue of $102 million Regulatory submission for SYFOVRE prefilled syringe planned for the first half of 2026EMPAVELI franchise has strong momentum with successful launch in C3G and primary IC-MPGN, and pivotal trials underway in FSGS and DGFCash and cash equivalents of $466 million as of December 31, 2025; projected revenues, cash, and cash equivalents expected to be sufficient to fund operations to profitabilityManagement to host conference call today at 8:30 a.m. ET WALTHAM, Mass., Feb. 24, 2026 (G

    2/24/26 7:05:00 AM ET
    $APLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Arcus Biosciences to Host Conference Call to Discuss Fourth-Quarter and Full-Year 2025 Financial Results and Pipeline Updates

    Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer and inflammatory and autoimmune diseases, announced that its management team will host a conference call and webcast on Wednesday, February 25th, 2026 at 1:30 PM PT / 4:30 PM ET to discuss details of the Company's financial results and pipeline update for the quarter and year ended December 31st, 2025. Investors interested in listening to the conference call may do so by dialing +1 (646) 844-6383 (local) or +1 (833) 470-1428 (toll-free), using Access Code: 190500. Participants may also register for the call onli

    2/11/26 4:05:00 PM ET
    $RCUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APLS
    $AXLA
    $CPHI
    $GMVD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Arcus Biosciences Inc.

    SC 13D/A - Arcus Biosciences, Inc. (0001724521) (Subject)

    12/17/24 9:52:58 PM ET
    $RCUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Apellis Pharmaceuticals Inc.

    SC 13G/A - Apellis Pharmaceuticals, Inc. (0001492422) (Subject)

    11/22/24 4:16:13 PM ET
    $APLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Apellis Pharmaceuticals Inc.

    SC 13G - Apellis Pharmaceuticals, Inc. (0001492422) (Subject)

    11/22/24 8:47:59 AM ET
    $APLS
    Biotechnology: Pharmaceutical Preparations
    Health Care